Sara Radcliffe, President and CEO of the California Life Sciences Association, discusses where Scott Gottlieb, M.D., is most likely to impact biopharma, and what the industry hopes he will accomplish as the FDA’s new commissioner.

Previous articleNew HIV Vaccine Strategy Could Be Key to Thwarting Virus
Next articleCorbin, Proteorex Partner on USP15 Inhibitors for Neuroinflammatory Disorders